Aurinia Pharmaceuticals (AUPH) Capital Expenditures (2020 - 2026)

Aurinia Pharmaceuticals (AUPH) has 7 years of Capital Expenditures data on file, last reported at $39000.0 in Q1 2026.

• Quarterly Capital Expenditures rose 129.41% year-over-year to $39000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$708000.0 (down 2623.08% YoY) and the FY2025 annual result came in at -$730000.0, down 2254.84% from the prior year.
• Capital Expenditures improved to $39000.0 in Q1 2026, from -$747000.0 in the prior quarter.
• In the past five years, Capital Expenditures ranged from a high of $507000.0 in Q2 2023 to a low of -$747000.0 in Q2 2025.
• A 5-year average of -$22866.7 and a median of $17000.0 in 2023 frame the typical range for Capital Expenditures.
• Annual changes were most pronounced in 2023 — Capital Expenditures soared 1200.0% — and 2025, when it slumped 683.59%.
• Tracing AUPH's Capital Expenditures over 5 years: stood at $205000.0 in 2022, then tumbled by 296.59% to -$403000.0 in 2023, then soared by 89.33% to -$43000.0 in 2024, then plunged by 1637.21% to -$747000.0 in 2025, then surged by 105.22% to $39000.0 in 2026.
• The last three Capital Expenditures figures came in at $39000.0 (Q1 2026), -$747000.0 (Q2 2025), and $17000.0 (Q1 2025), per Business Quant data.